Managed Healthcare Executive July 28, 2021
Peter Wehrwein

Wide ranging report covers a lot of ground. It sounds an optimistic note about biosimilars but is critical of white bagging.

Hospitals, health systems and other nonacute providers will spend 3.1% more on drugs next year, with oncology drugs accounting for roughly quarter of the expense, according to a report issued by Vizient today.

Vizient, historically a group purchasing organization for hospitals that now bills itself as healthcare performance improvement company, based the result on analysis of its members’ purchasing pharmaceutical data. The company, which is headquartered in Irving, Texas, also surveyed members about white bagging.

The report, titled the Summer 2021 Pharmacy Market Outlook, discusses the effect of the COVID-19 pandemic on drug expenditures and usage. Between April 2020...

Today's Sponsors

Canton & Company

Today's Sponsors

Curation Health

Today's Sponsor


Topics: Health System / Hospital, Provider, Survey / Study, Trends
The Post-pandemic future of clinical trials: How recruiting, participating and monitoring are changing
How pharma can help the post-COVID recovery of European cancer care
Clinical Trials In Crisis: Building On COVID-19’s Lessons Toward A Better Future
Providers, payers and pharma came together to tackle the COVID-19 pandemic. What's in store for the trio after the pandemic?
COVID vaccines an opportunity for Big Pharma to reset its reputation after decades of big profits and scandals